At-home health testing kit startup Everlywell has actually raised$ 75 million, following the close of the $175 million Series D it revealed in December. The brand-new funding comes from HealthQuest Capital, and sees the fund’s creator and handling partners Dr. Garheng Kong sign up with the company’s board of directors. The brand-new financing is a secondary sale, with proceeds utilized to offer liquidity to existing financiers rather than additional diluting shares, so the startup’s $1.3 billion evaluation from December still holds.
HealthQuest Capital’s investment portfolio has a heavy focus on commercialization of diagnostics businesses, and the business’s parent obviously has a board network of partners including health centers, and healthcare payers, both of which are going to be very tactically useful to Everlywell as it looks to scale its company on the enterprise side.
Austin-based Everlywell develops at-home screening kits for a variety of health concerns, including thyroid concerns, allergic reactions and food sensitivity. The company likewise included a COVID-19 home collection test set in 2020, and that has actually resulted in a lot of growth– both from the COVID test itself, and for its other series of products, according to Everlywell CEO and founder Julia Cheek, who I spoke with in December for the Series D raise.
Having HealthQuest’s endeavor arm on board as a partner might help it take its direct-to-consumer service and further develop a complementary enterprise operation. The business currently deals with employers and health insurance, but this need to absolutely help speed up that aspect of its business as it looks towards more development in 2021 and beyond.
Article curated by RJ Shara from Source. RJ Shara is a Bay Area Radio Host (Radio Jockey) who talks about the startup ecosystem – entrepreneurs, investments, policies and more on her show The Silicon Dreams. The show streams on Radio Zindagi 1170AM on Mondays from 3.30 PM to 4 PM.
Recent Comments